Biotechnology company OSE Immunotherapeutics (Euronext Paris:OSE) announced on Tuesday the launch of the Artemia trial to evaluate its cancer vaccine, Tedopi, in second-line treatment for metastatic non-small cell lung cancer (NSCLC).
The trial is being conducted in multiple countries and regions, including the United States, Canada, Europe and the United Kingdom.
Tedopi is a neoepitope-based vaccine designed to stimulate the immune system to target cancer cells. The Artemia trial will compare Tedopi to standard of care in HLA-A2 positive patients with NSCLC who have progressed after treatment with immune checkpoint inhibitors. The primary endpoint of the trial is overall survival.
OSE believes that Tedopi has the potential to address a significant unmet medical need for patients with advanced NSCLC.
The study is intended to support the registration of Tedopi, in parallel with the companion diagnostic for HLA-A2 positive patients.
NSCLC accounts for 85% of all lung cancers and the HLA-A2 phenotype represents about 45% of the population.
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial